Skip to main content
TipRanks
Go Ultimate75% OFF

Nrgene (NRGN) AI Stock Analysis

0 Followers
IL:NRGN

Nrgene

(TASE:NRGN)

Select Model
Rating:46Neutral
Price Target:ILA 59.00â–¼(-2.80% Downside)
Action:reiterated
Date:09/29/26

The overall score is heavily pressured by extremely weak technicals, with the stock in a deep downtrend and oversold conditions. Financial performance shows a transitional improvement with strong revenue growth and positive cash flow, but persistent unprofitability and a negative P/E ratio weigh on the valuation. The low debt and improving cash flow provide some stability, but the bearish market momentum is the most significant factor.

Positive Factors
Revenue and Gross Margin RecoveryThe sharp 2025 revenue rebound and substantial gross-margin improvement indicate stronger commercial activity and better unit economics. If these gains persist, they could provide a foundation for operating leverage, reinvestment, and improved earnings potential over the coming quarters.
Negative Factors
Persistent Operating and Net LossesThe sizable negative EBIT and net margins show that improved revenue and gross margin have not yet translated into sustainable operating earnings. Continued losses can consume equity, restrict internal investment capacity, and leave the business exposed if growth moderates.

Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)

-100%-75%-50%-25%0%25%50%IL:NRGN-78.51%EIS+10.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 8.03M
Dividend Yield
―
Average Volume (3M)
10.09K
Price to Earnings (P/E)
-0.9
Beta (1Y)
0.59
Revenue Growth
115.63%
EPS Growth
60.19%
Country
Israel
Employees
23
Sector
General
Sector Strength
55
Industry
Software - Application

Nrgene Business Overview & Revenue Model

Company Description

NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides spec...

How the Company Makes Money

NRGene primarily generates revenue by commercializing access to its genomics analysis software/platform and related services for organizations conducting genetic research and breeding programs. Key revenue streams typically include (a) software licen...

Nrgene Financial Statement Overview

Summary

Revenue surged 251% to $3.17M with improving gross margins, but the company remains unprofitable with a -47% net margin. The balance sheet is healthy with minimal debt (D/E 0.04), and cash flow turned modestly positive. Overall, a transitional phase with encouraging growth but persistent profitability risks.

Income Statement

45Neutral

Balance Sheet

65Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.25M3.17M1.29M2.00M3.16M4.46M
Gross Profit1.92M1.92M267.00K901.00K1.71M2.46M
EBITDA-1.98M-965.00K-2.69M-4.53M-5.59M-8.10M
Net Income-2.58M-1.50M-3.36M-5.24M-6.21M-8.34M
Balance Sheet
Total Assets7.12M9.54M6.00M10.79M17.30M26.36M
Cash, Cash Equivalents and Short-Term Investments3.18M5.30M1.37M6.45M12.28M22.87M
Total Debt145.02K181.00K288.00K797.00K1.61M3.34M
Total Liabilities4.66M5.13M2.00M3.57M5.04M8.68M
Stockholders Equity2.51M4.31M3.96M7.21M12.26M17.68M
Cash Flow
Free Cash Flow-511.43K72.00K-5.19M-5.58M-7.83M-6.67M
Operating Cash Flow268.11K855.00K-3.56M-3.91M-6.12M-5.57M
Investing Cash Flow364.72K455.00K-1.30M-1.27M12.47M-14.83M
Financing Cash Flow42.23K1.53M-317.00K-410.00K-2.46M27.59M

Nrgene Technical Analysis

Technical Analysis SentimentNegative
Last Price60.70

Price Trends

50DMA81.60Negative
100DMA135.20Negative
200DMA191.04Negative

Market Momentum

MACD-6.17Negative
RSI15.23Positive
STOCH88.03Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 60.70 is below the 20-day moving average (MA) of 66.19, below the 50-day MA of 81.60, and below the 200-day MA of 191.04, indicating a bearish trend. The MACD of -6.17 indicates Negative momentum. The RSI at 15.23 is Positive, neither overbought nor oversold. The STOCH value of 88.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.

Nrgene Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IL:NRGN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IL:MTRXIL:MTRX72OutperformILS 10.52B22.19―3.27%36.46%16.04%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IL:NRGNIL:NRGN46NeutralILS 8.06M-0.95――115.63%60.19%

* General Sector Average

Performance Comparison

-80%-60%-40%-20%0%IL:NRGNIL:MTRXIL:TECTIL:MPRSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:NRGN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:NRGNNRGENE TECHNOLOGIES LTD60.70-232.30-79.28%
IL:MTRXMatrix IT Ltd.11190.00-1653.07-12.87%
IL:TECTTECTONA LTD99.70-194.10-66.07%
IL:MPRSMediprss Pu45.60-15.40-25.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026